The firm’s Portable CMC is an open-source middleware that enhances the gene-to-IND supply chain, delivering speed, efficiency, predictability, and freedom to operate. The firm intends to complete a 500L scale CGMP cell banking and drug substance manufacturing facility in Oklahoma City, with the first batches of production set to commence in Q3 2023. The new facility will utilize integrated tools and technologies like Solentim, Ambr Microbioreactors, and DynaDrive Single-Use Bioreactors.
OKC’s pro soccer club to undergo community driven brand review
Process will involve regular listening sessions and consideration of a women’s team in the future